As EAH/EIN represents a pre-malignant endometrial disorder, and as GATA2 mechanisms are already implicated in malignancies of the prostate and bone marrow, it will also be critical to examine GATA2 levels and activity in endometrial malignancies to determine if GATA2 is also lost in these cancers and whether this contributes to disease pathobiology. This evidence concerns the gene GATA2 and endometrial disorder.